Market Overview:
The global monoclonal antibody treatment market is expected to grow at a CAGR of 10.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of cancer, autoimmune diseases, and infection across the globe. In addition, rising awareness about monoclonal antibody treatments and their benefits is also contributing to the growth of this market. Based on type, the global monoclonal antibody treatment market can be segmented into cancer, autoimmune diseases, infection, hematological diseases, and others. The cancer segment is expected to account for the largest share of this market in 2018 owing to rising incidence of various types of cancers across the globe. Based on application, hospitals are expected to account for the largest share of this market in 2018 followed by clinics.
Product Definition:
A monoclonal antibody treatment is a therapy that uses antibodies made from a single, specific clone of cells. These treatments are important because they can target proteins on cancer cells very specifically, which can minimize damage to healthy tissues.
Cancer:
Cancer is a group of diseases caused by abnormal cells that grow and multiply, without any control, to form a malignant tumor. Cancer generally means the uncontrolled growth of cells. Cancer can be either genetic or non-genetic in nature. Most cancers are genetic in origin and can be passed on from one generation to another through families (inherited cancer syndrome).
Autoimmune Diseases:
The global autoimmune diseases and it’s usage in monoclonal antibody treatment market size was valued at USD 7.2 billion in 2017. It is anticipated to expand at a CAGR of XX% during the forecast period, owing to rising prevalence of autoimmune disorders coupled with increasing geriatric population base across the globe.
Application Insights:
The application segment is segregated into hospitals, clinics, and others. The hospitals segment dominated the market in 2017 owing to the rising prevalence of chronic diseases such as cancer, autoimmune diseases, and infection that require a high number of monoclonal antibodies for treatment. Moreover, increasing government funding for research related to these aforementioned diseases drives the growth of this segment. For instance; in 2018 alone; China invested around USD 120 million in new drug development for various types of cancers including lung cancer and blood cancer.
Clinics are expected to be the fastest-growing application sector over the forecast period due largely to an increase in demand from emerging economies such as India and China where awareness regarding early diagnosis is high among consumers who have a higher preference for seeking treatment at clinics over hospitals due to affordability issues or convenience concerns.
Regional Analysis:
North America dominated the global monoclonal antibody treatment market in 2017. This can be attributed to favorable government initiatives, high healthcare expenditure, and availability of skilled physicians & clinical staff. Moreover, increasing prevalence of cancer is also expected to boost the demand for these products over the forecast period. For instance, according to statistics published by American Cancer Society in 2018; more than 1 million new cases were estimated to be diagnosed in U.S that year and about 600 thousand people died due to it.
Asia Pacific is expected witness lucrative growth during the forecast period owing its large population base suffering from chronic diseases such as cancer & autoimmune disorders which are highly responsiveto mAbs treatment along with rising awareness levels regarding these drugs among patients.
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for the monoclonal antibody treatment market. According to a study by the American Cancer Society, it is estimated that around 1,685,210 new cases of cancer will be diagnosed in 2017 in the U.S., and this number is expected to rise in the coming years. This will create a high demand for monoclonal antibody treatments and drive market growth.
- Rising prevalence of autoimmune diseases: The rising prevalence of autoimmune diseases is another key factor driving market growth. Autoimmune diseases are caused when an individual’s immune system mistakenly attacks their own body tissues and organs, resulting in inflammation and tissue damage. Monoclonal antibodies are used to treat various autoimmune diseases such as rheumatoid arthritis, Crohn’s disease, psoriasis, lupus erythematosus (Lupus), etc., which has led to an increase in their demand over the past few years.
Scope Of The Report
Report Attributes
Report Details
Report Title
Monoclonal Antibody Treatment Market Research Report
By Type
Cancer, Autoimmune Diseases, Infection, Hematological Diseases, Others
By Application
Hospitals, Clinics, Others
By Companies
Pfizer, Bayer, Sanofi, Merck, GlaxoSmithKline, Roche, Novartis, AbbVie
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
242
Number of Tables & Figures
170
Customization Available
Yes, the report can be customized as per your need.
Global Monoclonal Antibody Treatment Market Report Segments:
The global Monoclonal Antibody Treatment market is segmented on the basis of:
Types
Cancer, Autoimmune Diseases, Infection, Hematological Diseases, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Bayer
- Sanofi
- Merck
- GlaxoSmithKline
- Roche
- Novartis
- AbbVie
Highlights of The Monoclonal Antibody Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Cancer
- Autoimmune Diseases
- Infection
- Hematological Diseases
- Others
- By Application:
- Hospitals
- Clinics
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Monoclonal Antibody Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Monoclonal antibody treatment is a type of cancer treatment that uses antibodies to attack and kill cancer cells. Monoclonal antibodies are made from pieces of the immune systemu2019s own cells, which have been u201cclonedu201d or grown in large numbers. This makes them unique among cancer treatments because they can target specific types of cancer cells without harming healthy tissue.nnMonoclonal antibody therapy is often used in combination with other treatments, such as chemotherapy or radiation therapy, to improve the chances that it will be effective against the tumor. It can also be used alone if it is found early enough in the disease process.
Some of the key players operating in the monoclonal antibody treatment market are Pfizer, Bayer, Sanofi, Merck, GlaxoSmithKline, Roche, Novartis, AbbVie.
The monoclonal antibody treatment market is expected to grow at a compound annual growth rate of 10.8%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Monoclonal Antibody Treatment Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Monoclonal Antibody Treatment Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Monoclonal Antibody Treatment Market - Supply Chain
4.5. Global Monoclonal Antibody Treatment Market Forecast
4.5.1. Monoclonal Antibody Treatment Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Monoclonal Antibody Treatment Market Size (000 Units) and Y-o-Y Growth
4.5.3. Monoclonal Antibody Treatment Market Absolute $ Opportunity
5. Global Monoclonal Antibody Treatment Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Monoclonal Antibody Treatment Market Size and Volume Forecast by Type
5.3.1. Cancer
5.3.2. Autoimmune Diseases
5.3.3. Infection
5.3.4. Hematological Diseases
5.3.5. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Monoclonal Antibody Treatment Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Monoclonal Antibody Treatment Market Size and Volume Forecast by Application
6.3.1. Hospitals
6.3.2. Clinics
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Monoclonal Antibody Treatment Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Monoclonal Antibody Treatment Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Monoclonal Antibody Treatment Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Monoclonal Antibody Treatment Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Monoclonal Antibody Treatment Demand Share Forecast, 2019-2026
9. North America Monoclonal Antibody Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Monoclonal Antibody Treatment Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Monoclonal Antibody Treatment Market Size and Volume Forecast by Application
9.4.1. Hospitals
9.4.2. Clinics
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Monoclonal Antibody Treatment Market Size and Volume Forecast by Type
9.7.1. Cancer
9.7.2. Autoimmune Diseases
9.7.3. Infection
9.7.4. Hematological Diseases
9.7.5. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Monoclonal Antibody Treatment Demand Share Forecast, 2019-2026
10. Latin America Monoclonal Antibody Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Monoclonal Antibody Treatment Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Monoclonal Antibody Treatment Market Size and Volume Forecast by Application
10.4.1. Hospitals
10.4.2. Clinics
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Monoclonal Antibody Treatment Market Size and Volume Forecast by Type
10.7.1. Cancer
10.7.2. Autoimmune Diseases
10.7.3. Infection
10.7.4. Hematological Diseases
10.7.5. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Monoclonal Antibody Treatment Demand Share Forecast, 2019-2026
11. Europe Monoclonal Antibody Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Monoclonal Antibody Treatment Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Monoclonal Antibody Treatment Market Size and Volume Forecast by Application
11.4.1. Hospitals
11.4.2. Clinics
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Monoclonal Antibody Treatment Market Size and Volume Forecast by Type
11.7.1. Cancer
11.7.2. Autoimmune Diseases
11.7.3. Infection
11.7.4. Hematological Diseases
11.7.5. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Monoclonal Antibody Treatment Demand Share, 2019-2026
12. Asia Pacific Monoclonal Antibody Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Monoclonal Antibody Treatment Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Monoclonal Antibody Treatment Market Size and Volume Forecast by Application
12.4.1. Hospitals
12.4.2. Clinics
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Monoclonal Antibody Treatment Market Size and Volume Forecast by Type
12.7.1. Cancer
12.7.2. Autoimmune Diseases
12.7.3. Infection
12.7.4. Hematological Diseases
12.7.5. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Monoclonal Antibody Treatment Demand Share, 2019-2026
13. Middle East & Africa Monoclonal Antibody Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Monoclonal Antibody Treatment Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Monoclonal Antibody Treatment Market Size and Volume Forecast by Application
13.4.1. Hospitals
13.4.2. Clinics
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Monoclonal Antibody Treatment Market Size and Volume Forecast by Type
13.7.1. Cancer
13.7.2. Autoimmune Diseases
13.7.3. Infection
13.7.4. Hematological Diseases
13.7.5. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Monoclonal Antibody Treatment Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Monoclonal Antibody Treatment Market: Market Share Analysis
14.2. Monoclonal Antibody Treatment Distributors and Customers
14.3. Monoclonal Antibody Treatment Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Pfizer
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Bayer
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Sanofi
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Merck
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. GlaxoSmithKline
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Roche
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Novartis
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. AbbVie
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook